GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MedReleaf Corp (OTCPK:MEDFF) » Definitions » Current Accrued Expense

MedReleaf (MedReleaf) Current Accrued Expense : $0.00 Mil (As of Mar. 2018)


View and export this data going back to 2017. Start your Free Trial

What is MedReleaf Current Accrued Expense?

MedReleaf's Current Accrued Expense for the quarter that ended in Mar. 2018 was $0.00 Mil.


MedReleaf Current Accrued Expense Historical Data

The historical data trend for MedReleaf's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedReleaf Current Accrued Expense Chart

MedReleaf Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18
Current Accrued Expense
- - - - -

MedReleaf Quarterly Data
Mar14 Mar15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MedReleaf Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


MedReleaf Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of MedReleaf's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


MedReleaf (MedReleaf) Business Description

Traded in Other Exchanges
N/A
Address
MedReleaf Corp is engaged in the production and sale of cannabis for medical purposes as regulated by the ACMPR, pursuant to its Licences and, in particular, its Markham Commercial Licence.